Profile data is unavailable for this security.
About the company
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
- Revenue in USD (TTM)1.40bn
- Net income in USD177.69m
- Incorporated2004
- Employees4.70k
- LocationPenumbra IncOne Penumbra PlaceALAMEDA 94502United StatesUSA
- Phone+1 (302) 531-0855
- Fax+1 (302) 531-3150
- Websitehttps://www.penumbrainc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Rad Laboratories Inc | 2.58bn | 759.90m | 7.49bn | 7.45k | 10.02 | 1.01 | 8.10 | 2.90 | 27.91 | 27.91 | 94.69 | 276.16 | 0.2591 | 1.65 | 5.66 | 346,738.30 | 7.62 | -1.69 | 8.02 | -1.77 | 52.01 | 54.52 | 29.42 | -8.08 | 4.19 | -- | 0.139 | -- | 0.6507 | 0.2935 | 141.20 | -27.58 | 7.74 | -- |
| Masimo Corp | 1.53bn | 207.70m | 9.16bn | 2.20k | 45.25 | 12.67 | 37.16 | 6.00 | 3.88 | -2.77 | 28.42 | 13.84 | 0.7062 | 1.39 | 4.42 | 694,045.40 | 9.61 | 5.65 | 12.45 | 6.99 | 61.90 | 58.51 | 13.60 | 9.43 | 1.47 | 8.39 | 0.421 | 0.00 | 9.44 | 5.95 | 1,182.10 | -2.87 | -20.94 | -- |
| Henry Schein Inc | 13.18bn | 398.00m | 9.33bn | 25.00k | 24.88 | 2.90 | 13.00 | 0.7079 | 3.27 | 3.27 | 108.32 | 28.03 | 1.23 | 4.76 | 8.42 | 527,360.00 | 3.80 | 5.06 | 6.56 | 8.59 | 31.14 | 30.81 | 3.09 | 3.79 | 0.7627 | 6.54 | 0.3932 | 0.00 | 4.03 | 5.43 | 2.05 | -0.2399 | 31.36 | -- |
| Baxter International Inc | 11.24bn | -900.00m | 10.13bn | 37.50k | -- | 1.65 | 125.07 | 0.901 | -1.75 | -1.87 | 21.89 | 11.92 | 0.4906 | 3.64 | 6.14 | 299,840.00 | -3.93 | -2.30 | -4.96 | -2.83 | 30.68 | 36.76 | -8.00 | -5.74 | 1.56 | 2.67 | 0.6083 | -- | 5.72 | -0.7461 | -167.06 | -- | -6.27 | -11.45 |
| Revvity Inc | 2.86bn | 239.88m | 10.69bn | 11.00k | 46.14 | 1.48 | 16.56 | 3.74 | 2.07 | 2.08 | 24.49 | 64.57 | 0.2326 | 3.46 | 4.15 | 259,641.00 | 1.95 | 3.23 | 2.13 | 3.58 | 54.77 | 58.48 | 8.40 | 13.58 | 1.40 | 5.01 | 0.3075 | 8.08 | 3.67 | -5.47 | -15.26 | -19.91 | -1.05 | 0.00 |
| Guardant Health Inc | 982.02m | -416.28m | 12.10bn | 2.49k | -- | -- | -- | 12.32 | -3.31 | -3.31 | 7.83 | -0.7602 | 0.5613 | 4.45 | 7.92 | 394,385.90 | -23.79 | -25.70 | -28.02 | -28.93 | 64.46 | 63.20 | -42.39 | -76.30 | 4.56 | -- | 1.07 | -- | 32.88 | 27.92 | 4.61 | -- | -2.23 | -- |
| Solventum Corp | 8.33bn | 1.56bn | 12.66bn | 20.00k | 8.23 | 2.51 | 6.19 | 1.52 | 8.87 | 8.87 | 47.48 | 29.10 | 0.5791 | 3.81 | 8.01 | 416,250.00 | 10.82 | -- | 13.58 | -- | 53.57 | 56.92 | 18.69 | 15.05 | 0.8906 | 2.05 | 0.4993 | -- | 0.8602 | 2.72 | 224.84 | 6.46 | 6.94 | -- |
| Globus Medical Inc | 2.94bn | 537.87m | 12.69bn | 6.00k | 23.84 | 2.77 | 15.55 | 4.32 | 3.93 | 3.93 | 21.44 | 33.86 | 0.5569 | 1.35 | 4.75 | 489,821.80 | 10.19 | 6.18 | 11.69 | 6.89 | 67.41 | 66.20 | 18.30 | 12.25 | 2.74 | -- | 0.0002 | 0.00 | 16.65 | 30.08 | 422.28 | 39.37 | 22.34 | -- |
| Penumbra Inc | 1.40bn | 177.69m | 13.43bn | 4.70k | 75.68 | 9.41 | 68.83 | 9.57 | 4.52 | 4.52 | 35.73 | 36.39 | 0.8356 | 1.10 | 7.85 | 298,652.10 | 10.58 | 4.03 | 11.77 | 4.49 | 67.14 | 64.57 | 12.66 | 5.39 | 4.29 | -- | 0.0159 | 0.00 | 17.50 | 20.16 | 1,168.11 | -- | 20.82 | -- |
| Align Technology Inc | 4.03bn | 410.35m | 13.47bn | 20.29k | 33.40 | 3.33 | 20.80 | 3.34 | 5.66 | 5.66 | 55.59 | 56.74 | 0.6483 | 5.33 | 3.85 | 198,864.70 | 6.59 | 8.11 | 9.67 | 11.97 | 68.27 | 70.62 | 10.17 | 12.31 | 1.24 | -- | 0.00 | 0.00 | 0.899 | 10.30 | -2.61 | -25.40 | -7.94 | -- |
| Cooper Companies Inc | 4.09bn | 374.90m | 16.37bn | 15.00k | 44.79 | 2.00 | 21.77 | 4.00 | 1.87 | 1.87 | 20.46 | 42.06 | 0.3312 | 1.71 | 5.29 | 272,826.70 | 3.03 | 8.04 | 3.32 | 8.86 | 65.54 | 66.01 | 9.16 | 24.66 | 1.13 | 6.32 | 0.2332 | 0.2049 | 5.06 | 10.98 | -4.44 | 9.48 | 3.15 | -- |
| Hologic Inc | 4.13bn | 543.80m | 16.84bn | 7.07k | 31.31 | 3.21 | 20.07 | 4.08 | 2.41 | 2.41 | 18.28 | 23.51 | 0.4608 | 2.57 | 6.79 | 583,663.40 | 6.07 | 11.22 | 6.82 | 12.85 | 56.51 | 60.20 | 13.18 | 21.99 | 3.32 | 15.76 | 0.3246 | 0.00 | 1.74 | 1.66 | -28.35 | -12.69 | -0.5168 | -- |
| Insulet Corp | 2.71bn | 247.10m | 17.28bn | 5.40k | 70.12 | 11.40 | 51.18 | 6.38 | 3.50 | 3.50 | 37.86 | 21.53 | 0.8628 | 1.74 | 6.14 | 501,518.50 | 7.87 | 7.14 | 9.75 | 8.51 | 71.63 | 68.72 | 9.13 | 10.06 | 2.15 | 46.91 | 0.3852 | 0.00 | 30.73 | 24.53 | -40.93 | 105.15 | 5.67 | -- |
| West Pharmaceutical Services Inc | 3.07bn | 493.70m | 18.10bn | 10.80k | 36.98 | 5.70 | 27.81 | 5.89 | 6.79 | 6.79 | 42.28 | 44.11 | 0.7769 | 4.80 | 5.40 | 284,638.90 | 12.11 | 15.24 | 14.29 | 18.19 | 35.91 | 37.89 | 15.59 | 18.67 | 2.34 | -- | 0.0614 | 10.13 | 6.25 | 7.44 | 0.203 | 7.36 | 10.39 | 5.51 |
Data as of Mar 03 2026. Currency figures normalised to Penumbra Inc's reporting currency: US Dollar USD
47.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 4.48m | 11.43% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.57m | 9.11% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.47m | 8.85% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 1.61m | 4.10% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.16m | 2.95% |
| Citadel Advisors LLCas of 31 Dec 2025 | 979.19k | 2.50% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 876.33k | 2.23% |
| RTW Investments LPas of 31 Dec 2025 | 866.50k | 2.21% |
| Geode Capital Management LLCas of 31 Dec 2025 | 766.51k | 1.95% |
| ClearBridge Investments LLCas of 31 Dec 2025 | 690.81k | 1.76% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
